Company news

Rapport Therapeutics, Inc. news in 2025

Rapport Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

December 4, 2025

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

November 24, 2025

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

November 5, 2025

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 4, 2025

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 10, 2025

Rapport Announces Pricing of Public Offering of Common Stock

September 8, 2025

Rapport Announces Proposed Public Offering of Common Stock

September 7, 2025

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

September 7, 2025

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

September 4, 2025

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

August 6, 2025

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

June 1, 2025

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 26, 2025

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 20, 2025

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 7, 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

March 20, 2025

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 10, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

March 2, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

January 8, 2025

Decks in 2025